Close
Close

AI-Driven Peptide Library Design & Screening Service by Yeast Display

Services Workflow Platform Advantages Related Services FAQ

Overcome Screening Barriers with AI‑Integrated Yeast Display

For researchers pursuing peptide therapeutics against intractable targets, library size limitations and lengthy screening processes remain major barriers to progress. Creative Biolabs' AI‑integrated yeast display service bridges this gap uniquely: it leverages initial screening data to build custom ML models, which generate and prioritize high‑affinity‑rich second‑generation libraries without extra wet‑lab efforts. Our closed‑loop workflow significantly speeds up the discovery of optimal peptide candidates.

Explore Related Solutions

Fig. 1 Observation (Creative Biolabs AI)

Yeast Display based MHC-Peptide Discovery

Identify immunogenic peptide candidates for vaccine development or TCR‑directed therapeutics.

Fig. 2 Petri dish (Creative Biolabs AI)

Yeast Display‑based Evolutionary Optimization of Peptide

Improve affinity, stability, or selectivity of existing peptide leads through iterative mutagenesis and selection.

Fig. 3 Setting (Creative Biolabs AI)

Yeast Display based Ligand‑Receptor Interaction

Map binding interfaces and discover competitive peptide ligands.

Fig. 4 Bio Scope (Creative Biolabs AI)

Yeast Display based PTM Analysis in Peptide

Study phosphorylation, glycosylation, and other modifications.

Discuss with Us →

From Target Definition to Data Delivery: Our End‑to‑End Workflow

Starting Materials
Synthetic peptide‑displaying yeast libraries, purified target antigen, or client‑provided sequence templates.

Fig. 5 Synergy (Creative Biolabs AI)
Round 1 Screening
High‑throughput selection (e.g., FACS) against the target.
Fig. 6 Pathogen (Creative Biolabs AI)
Model Training
Machine learning (deep learning / generative models) learns sequence‑activity relationships from screening data.
Fig. 7 Safeguard (Creative Biolabs AI)
In Silico Library Design
Algorithm generates a second‑generation library with predicted higher affinity, exploring sequence space beyond 109 physical diversity.
Fig. 8 Uplift (Creative Biolabs AI)
Validation
Selected in silico designs are synthesized, displayed, and screened for confirmation.
Deliverables
Fig. 9 Inventory (Creative Biolabs AI)
  • Primary screening datasets (enriched sequences, binding profiles).
  • Trained AI model (proprietary, used for your project).
  • Validated second‑generation hit peptides with affinity data.
  • Final report including experimental vs. predicted ranking.

Learn More About Our Process →

Our Yeast Display Core: Where Biology Meets Computation

Creative Biolabs' yeast display platform combines mature yeast surface engineering with quantitative flow cytometry. Key features include eukaryotic post‑translational modification fidelity, tight quality control of expression levels, and full compatibility with fluorescence‑activated cell sorting (FACS) for multi‑parameter selection. The platform routinely handles libraries in the 108-109 range and integrates seamlessly with downstream AI analytics.
Yeast Display Platform - Creative Biolabs

Evaluate Your Target with Our Platform →

Why Smart Teams Choose Us: Differentiators + Proof Points

Fig. 10 Atom (Creative Biolabs AI)

Breakthrough library size limitation
Algorithmic simulation explores sequence space far beyond the physical 109 barrier, effectively covering billions of additional variants in silico.

Fig. 11 Dossier (Creative Biolabs AI)

Accelerated convergence
Drastically reduces screening rounds (often from 4-5 rounds to 2-3), pinpointing optimal sequences faster and saving months of lab work.

Fig. 12 Ingenuity (Creative Biolabs AI)

Post‑translational modification fidelity
Eukaryotic expression ensures peptides fold and modifies correctly, avoiding bacterial display artefacts.

Fig. 13 Vessel (Creative Biolabs AI)

High‑throughput FACS
Isolates rare high‑affinity clones with quantitative resolution.

Fig. 14 Gear (Creative Biolabs AI)

Applicable to undruggable targets
Proven on protein interactions, toxic antigens, and membrane proteins.

Fig. 15 Circulation (Creative Biolabs AI)

Multi‑objective optimization
Simultaneously optimize affinity, stability, specificity, or expression yield.

Get a Tailored Estimate for Your Project →

Explore Related Solutions

Explore our complete suite of yeast display technology offerings

Yeast Display Library Construction

Custom library design and construction covering diverse peptide scaffolds and diversities.

Yeast Display Library Screening

High‑throughput FACS‑based screening against soluble, membrane‑bound, or complex antigen targets.

Yeast Display-Based Antibody Affinity Maturation

Rationally improve antibody lead affinity and biophysical properties.

Yeast Display-Based T Cell Receptor Engineering

Enhance TCR specificity, affinity, or stability for cell therapy applications.

Human Monoclonal Antibody Identification

Full human antibody discovery from naïve or immune yeast display libraries.

Yeast Display based Antibody Discovery

End‑to‑end antibody hit generation against challenging targets.

Yeast Display based Protein Optimization and Engineering

Improve expression, stability, or activity of protein leads through directed evolution.

Explore All Solution →

Your Most Pressing Technical Questions, Answered

  1. How does AI reduce the number of screening rounds compared to traditional yeast display?

    Traditional methods require iterative enrichment rounds (often 4-5) to converge. With AI, primary screening data trains a model that predicts high‑affinity variants in silico. Researchers then directly validate a second‑generation library, effectively skipping intermediate rounds.

  2. Can the platform handle multi‑parameter optimization (e.g., affinity + stability + specificity)?

    Yes. The screening workflow can incorporate FACS gating for multiple parameters simultaneously. The AI model can also be trained on combined readouts (binding, expression level, off‑target reactivity) to propose sequences balancing all desired properties.

  3. What input do clients need to start an AI‑driven library design project?

    At minimum: target antigen (purified protein or peptide) and desired peptide length / scaffold constraints. Existing hit sequences or preliminary binding data are optional but accelerate model training.

  4. How do you validate the in silico predictions experimentally?

    The second‑generation library is synthesized, displayed on yeast, and screened against the target. Validation includes direct binding measurements (EC50/IC50) for top predicted hits and comparison of experimental vs. predicted rankings.

  5. Does Creative Biolabs offer downstream expression or validation services after screening?

    Yes. Clients can access recombinant peptide synthesis, expression in mammalian systems, SPR/biolayer interferometry for kinetics, and cell‑based activity assays – all under one roof.

Obtain a tailored proposal for your target


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us